SIMRIS_B: EBITDA loss narrowed 51% in Q2, but liquidity remains a critical concern

About this update from Simris Group Ab Class B

Q2 2025 saw improved EBITDA and EBIT losses, but interim revenue declined 27% year-over-year. Cash reserves are low, with urgent funding needs, while the company advances preclinical oncology programs and winds down legacy operations.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Simris Group Ab Class B